The IP6K1 Knockout HEK293T Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HEK293T embryonic kidney epithelial cell line, engineered to disrupt the inositol hexakisphosphate kinase 1 (IP6K1) gene. This pooled population of edited cells provides a loss-of-function model for studying inositol pyrophosphate signaling without clonal isolation, enabling more representative functional analyses.
In biomedical research, HEK293T cells are a foundational model system, originally derived from human embryonic kidney cells and immortalized through the integration of adenovirus 5 E1A/E1B genes, which enable robust protein expression and susceptibility to lentiviral transduction. The additional stable expression of SV40 large T-antigen promotes episomal replication of vectors containing the SV40 origin, making this line particularly valuable for high?yield recombinant protein production, lentivirus packaging, and transient transfection?based signaling studies.
IP6K1 catalyzes the conversion of inositol hexakisphosphate (IP6) to 5?diphosphoinositol pentakisphosphate (5?IP7), a critical inositol pyrophosphate second messenger. In HEK293T cells, IP6K1 acts downstream of insulin and IGF?1 receptor signaling, regulated by PI3K and mTORC2. The product 5?IP7 modulates AKT activation by inhibiting PDK1, thereby controlling phosphorylation of GSK3?? and p53. IP6K1 also interacts with protein kinase CK2 and importin??? and contributes to actin cytoskeleton regulation. Disruption of IP6K1 depletes 5?IP7, leading to dysregulated AKT phosphorylation, altered actin filament architecture, and impaired DNA repair.
This knockout model in HEK293T cells enables precise investigation of the intersection between inositol pyrophosphate metabolism and the PI3K/AKT signaling axis. Since HEK293T cells express insulin signaling machinery including IRS1 and GLUT4, IP6K1 loss disrupts insulin?stimulated AKT(Ser473) phosphorylation, mimicking insulin resistance phenotypes. The absence of 5?IP7 also decouples mTORC2?dependent regulation of AKT and sensitizes cells to apoptosis, providing a relevant platform for metabolic disease and cancer studies. The polyclonal nature of the knockout population reduces clonal adaptation artifacts, offering a more physiologically representative model for pathway dissection.
This polyclonal knockout line is suited for insulin signaling studies, with AKT phosphorylation monitored by western blotting or flow cytometry. Metabolic gene expression analysis via RT?qPCR, actin cytoskeletal imaging by immunofluorescence, and IP7 quantification by HPLC or mass spectrometry enable comprehensive pathway validation. The cells support drug?target validation for metabolic syndrome and cancer, facilitating IP6K1 inhibitor screening. Additionally, DNA repair and apoptosis assays, including Annexin V staining and cell cycle profiling, provide complementary phenotypic readouts. For custom assay development or screening campaigns, please contact Ascent Research.
